YIBAI PHARMACEUTICAL(SH:600594) Zheng Quan Zhi Xing·2025-09-05 11:12Core Viewpoint - The legal opinion confirms that the procedures for convening and holding the 2025 First Extraordinary General Meeting of Guizhou Yibai Pharmaceutical Co., Ltd. comply with relevant laws and regulations, ensuring the legitimacy of the meeting and its resolutions [1][10]. Group 1: Meeting Procedures - The company announced the meeting on August 21, 2025, and published relevant materials on August 28, 2025, in compliance with legal requirements [2][3]. - The meeting was scheduled for September 5, 2025, and was conducted using a combination of on-site and online voting methods [3][4]. - The notice included details such as meeting type, time, location, and voting procedures, meeting the requirements of the Company Law and other regulations [4][9]. Group 2: Attendance and Qualifications - Shareholders registered by the close of trading on August 29, 2025, were eligible to attend the meeting, along with company directors, supervisors, and legal representatives [5][6]. - A total of 348 participants attended the meeting, representing 187,535,236 shares, which is approximately 1.06% of the total shares [5][6]. Group 3: Voting Procedures and Results - The meeting's voting was conducted through a named voting method, with all proposed resolutions receiving overwhelming support, with approval rates ranging from 98.11% to 98.65% [6][8]. - All resolutions, including the cancellation of the supervisory board and amendments to various internal regulations, were passed [7][8][9]. - The voting process and results were verified to be in accordance with the Company Law and other relevant regulations, confirming the legitimacy of the meeting's outcomes [9][10].